Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
Leqembi, an Alzheimer's drug from Biogen and Eisai, offers early-stage patients more independent living time but faces hurdles like reimbursement issues, diagnostic tests, and neurologist availability. Missie Meeks, an early recipient, reports improved daily functioning. Despite risks like brain swelling and bleeding, some patients find the process worth it for extended normal life.
Highlighted Terms
Related News
Leqembi, an Alzheimer's drug from Biogen and Eisai, promises to extend patients' normal, independent lives, though it's not a cure. Missie Meeks, diagnosed with early Alzheimer's, benefits from Leqembi, which moderately slows cognitive decline. However, the drug's rollout faces challenges like insurance hurdles and limited neurologist availability. Despite risks of brain swelling and bleeding, some patients find the process worth it for extended quality time with loved ones.
Leqembi, an Alzheimer's drug from Biogen and Eisai, offers early-stage patients more independent living time but faces hurdles like reimbursement issues, diagnostic tests, and neurologist availability. Missie Meeks, an early recipient, reports improved daily functioning. Despite risks like brain swelling and bleeding, some patients find the process worth it for extended normal life.